Chidamide treatment for intermediate-to-high-risk bone marrow disease
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests whether a drug called chidamide can help patients with myelodysplastic syndromes (MDS)—a blood condition where bone marrow doesn't make enough healthy blood cells. The drug may help your bone marrow work better and reduce anemia and other blood problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older
- You have been diagnosed with MDS (myelodysplastic syndromes) and it is intermediate-to-high risk
- Your bone marrow has fewer than 15% abnormal blast cells
- You have had low blood cell counts for at least 4 months
- Your heart, liver, and kidney function are adequate
- You have not received chidamide before and have not had certain cancer treatments in the past 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests a combination of three drugs (chidamide, an angiogenesis inhibitor, and fulvestrant) for advanced HR+ / HER2- breast cancer. It is for patients who have already tried a CDK4/6 inhibitor and need a new treatment option.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.